Authors

• Teruyuki Hirano (ORCID: https://orcid.org/0000-0003-2094-2428)
• Yasuyuki Iguchi (ORCID: https://orcid.org/0000-0002-6662-0611)
• Hirotada Maeda (ORCID: https://orcid.org/0009-0006-3182-2156)
• Kanta Tanaka (ORCID: https://orcid.org/0000-0002-3291-5083)
• Ḱazunori Toyoda (ORCID: https://orcid.org/0000-0002-8346-9845)
• Katsuhiro Omae (ORCID: https://orcid.org/0000-0001-6722-3311)
• Masafumi Ihara (ORCID: https://orcid.org/0000-0002-7102-4048)
• Masatoshi Koga (ORCID: https://orcid.org/0000-0002-6758-4026)
• Nobuyuki Sakai (ORCID: https://orcid.org/0000-0002-3289-1210)
• Teruo Noguchi (ORCID: https://orcid.org/0000-0001-5372-4932)
• Koko Asakura
• Manabu Sakaguchi (ORCID: https://orcid.org/0000-0001-9046-4703)
• Haruko Yamamoto (ORCID: https://orcid.org/0000-0002-8135-2547)
• Hiroshi Yamagami (ORCID: https://orcid.org/0000-0001-8133-3314)
• Shuhei Okazaki (ORCID: https://orcid.org/0000-0002-5789-2893)
• Shiro Yamamoto

Institutions

• Jikei University School of Medicine (JP)
• University of Tsukuba (JP)
• Kyorin University (JP)
• Osaka Prefectural Medical Center (JP)
• Osaka National Hospital (JP)
• Shizuoka City Shimizu Hospital (JP)
• Osaka City General Hospital (JP)
• National Cerebral and Cardiovascular Center (JP)
• The University of Osaka (JP)

Publication Details

Journal

Frontiers in Neurology

Published

2024-10-23

DOI

https://doi.org/10.3389/fneur.2024.1468523

Citations

1

Primary Topic

Antiplatelet Therapy and Cardiovascular Diseases

Type

article

Field-Weighted Citation Impact

0.40

Funders

• Bristol-Myers Squibb
• Pfizer